Jon Aning

North Bristol NHS Trust, Southmead Hospital

Papers

5

Total Citations

446

H-Index

5

About

Jon Aning is a leading urological surgeon and researcher whose work centers on improving surgical outcomes for patients with bladder and prostate cancers. His major contributions lie in two pivotal areas: evaluating the benefits of robot-assisted surgery and preserving nerve function during prostatectomy. Aning was the lead author of a landmark 2022 study in *JAMA* comparing robot-assisted radical cystectomy with intracorporeal urinary diversion to open surgery, which found no significant difference in 90-day morbidity or mortality—a finding that has shaped clinical practice and garnered over 320 citations. He also spearheaded the NeuroSAFE PROOF trials, investigating a real-time frozen section technique to spare neurovascular bundles during robot-assisted radical prostatectomy. This work demonstrated that NeuroSAFE-guided surgery can improve erectile function and early urinary continence without compromising cancer control, with results published in a 2025 phase 3 trial. Additionally, Aning has contributed to health economics, showing that robot-assisted cystectomy may be cost-effective. His research, cited over 400 times, directly addresses the trade-offs between oncologic control and quality of life, making him a key voice in evidence-based surgical innovation.

Research Focus

Key Achievements

5
H-Index
5
Papers
446
Total Citations
89
Avg Citations/Paper
🏆 Most Cited Paper
Effect of Robot-Assisted Radical Cystectomy With Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients With Bladder Cancer
320 citations · 2022
📈 Most Prolific Year: 2022 (2 Papers)
🤝 Key Collaborators: 102
🏛 Institutions: North Bristol NHS Trust, Southmead Hospital

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago